



# PIPELINE

Category	Targets	Modality	Indications	Affinity KD	ELISA EC50	ELISA IC50	Cell EC50	Cell IC50	Animal efficacy	Non-GLP animal study	Molecule Differentiation
Obesity	ActRII	mAb	Muscle loss						Q2/25	Q3/25	Gain lean mess, long-acting, SC injection
	ActRII/ GLP-1RA	mAb/ fusion protein	Obesity/ muscle loss						Q2/25	Q3/25	Weight loss w/lean mess gaining, long-acting (FIC), SC injection
	Myostatin	mAb	Muscle loss						Q1/25	Q2/25	Gain lean mess, long-acting, SC injection
	Myostatin/ GLP-1RA	mAb/ fusion protein	Obesity/ muscle loss						Q1/25	Q2/25	Weight loss w/lean mess gaining, long-acting (FIC), SC injection
	GIPR/ GLP-1RA	mAb/ fusion protein	Obesity						Q2/25	Q2/25	Weight loss, long-acting, SC injection
Oncology	BTLA	mAb	Solid tumor						Q2/25	Q2/25	New immune checkpoint, long-acting
	BTLA/PD-1	BsAb	Solid tumor						Q2/25	Q4/25	FIC, long-action
Autoimmune	BAFF-R	mAb	Sjogren's syndrome, SLE						Q2/25	Q2/25	Long-acting
	BAFF-R/CD3	BsAb	B cell-related autoimmune diseases						Q2/25	Q4/25	potential FIC, long-action, SC injection
	BAFF-R/ CD20/CD3	TriAb	B cell-related autoimmune diseases						Q3/25	Q4/25	FIC, long-acting, SC injection
	BAFF-R/ CD19/CD3	TriAb	B cell-related autoimmune diseases						Q3/25	Q4/25	FIC, long-acting, SC injection

# GREAT BAY BIO LIMITED

✉ [BD@greatbay-bio.com](mailto:BD@greatbay-bio.com)

☎ (+852) 31023232

📍 Unit 105-106, Biotech Centre 2,  
Hong Kong Science Park, Shatin, Hong Kong

